Phase I/II trial of perioperative avelumab in combination with chemoradiation (CRT) in the treatment of stage II/III resectable esophageal and gastroesophageal junction (E/GEJ) cancer.

被引：0
|
作者：
Uboha, Nataliya Volodymyrivna
Eickhoff, Jens C.
Maloney, James D.
McCarthy, Daniel
DeCamp, Malcolm
Deming, Dustin A.
LoConte, Noelle K.
Matkowskyj, Kristina A.
Patel, Monica Arun
Hurst, Newton
Kratz, Jeremy D.
Lubner, Sam Joseph
Bassetti, Michael Frederick
机构：
[1] UW Carbone Canc Ctr, Madison, WI USA
[2] Univ Wisconsin, Dept Biostat, Madison, WI USA
[3] Univ Wisconsin, Div Cardiothorac Surg, Dept Surg, Madison, WI USA
[4] Univ Wisconsin, Madison, WI USA
[5] ECOG ACRIN, Madison, WI USA
[6] Univ Michigan, Ann Arbor, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4034
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I/II trial of perioperative avelumab in combination with chemoradiation in the treatment of stage II/III resectable esophageal cancer.
    Uboha, Nataliya Volodymyrivna
    Maloney, James D.
    McCarthy, Daniel
    Deming, Dustin A.
    LoConte, Noelle K.
    Matkowskyj, Kristina
    Eickhoff, Jens C.
    Mulkerin, Daniel
    DeCamp, Malcolm M.
    Lubner, Sam Joseph
    Turk, Anita Ahmed
    Bassetti, Michael Frederick
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [2] Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer.
    Uboha, Nataliya Volodymyrivna
    Maloney, James D.
    McCarthy, Daniel
    Deming, Dustin A.
    LoConte, Noelle K.
    Matkowskyj, Kristina
    Eickhoff, Jens C.
    Emmerich, Philip
    DeCamp, Malcolm M.
    Lubner, Sam Joseph
    Turk, Anita Ahmed
    Bassetti, Michael Frederick
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer.
    Adelstein, DJ
    Rybicki, LA
    Carroll, MA
    Rice, TW
    Mekhail, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 321S - 321S
  • [4] Phase Ib/II trial of durvalumab and chemoradiation (CRT) with carboplatin/paclitaxel for esophageal and gastroesophageal junction (GEJ) adenocarcinoma.
    Greally, Megan
    Molena, Daniela
    Sihag, Smita
    Wu, Abraham Jing-Ching
    Shah, Pari M.
    Fein, Carly
    Capanu, Marinela
    Kelsen, David Paul
    Janjigian, Yelena Yuriy
    Ilson, David H.
    Ku, Geoffrey Yuyat
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [5] Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer.
    Kelly, Ronan Joseph
    Smith, Kellie Nicole
    Anagnostou, Valsamo
    Thompson, Elizabeth
    Hales, Russell K.
    Battafarano, Richard J. James
    Voong, K. Ranh
    Yang, Stephen C.
    Feliciano, Josephine Louella
    Shin, Eun Ji
    Hu, Chen
    El Asmar, Margueritta
    Chan, Hok Yee
    Velculescu, Victor E.
    Sears, Cynthia
    Pardoll, Drew M.
    Amjad, Ali Imran
    Guerrieri, Patrizia
    Jobe, Blair Anderson
    Zaidi, Ali Hussainy
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [6] Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response observed in adenocarcinoma
    Ilson, D.
    Janjigian, Y. Y.
    Shah, M. A.
    Tang, L. H.
    Kelsen, D. P.
    Campbell, J.
    Fuqua, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [7] A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers
    Ko, A. H.
    Noel, M.
    Chao, J.
    Sohal, D.
    Crow, M.
    Oberstein, P. E.
    Scott, A.
    Mcree, A.
    Lima, C. Rocha
    Fong, L.
    Keenan, B.
    Filbert, E.
    Hsu, F. J.
    Shankaran, V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1111 - S1111
  • [8] MONEO: A phase II study of avelumab plus FLOT in the perioperative treatment for patients with resectable gastric or gastroesophageal junction cancer
    Alsina, M.
    Ponz-Sarvise, M.
    Lopez Garcia, D.
    Gonzalez, M.
    De Andrea, C.
    Gros, A.
    Vivancos, A.
    Jimenez Fonseca, P.
    Diez, M.
    Arrazubi, V.
    Sanz-Garcia, E.
    Martinez de Castro, E.
    Guardeno Sanchez, R.
    Calvo Campos, M.
    Buges Sanchez, C.
    Munoz, F.
    Tabernero, J.
    Villacampa, G.
    Munoz, S.
    Melero, I.
    ANNALS OF ONCOLOGY, 2021, 32 : S155 - S156
  • [9] Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response observed in adenocarcinoma.
    Ilson, D.
    Shah, M. A.
    Kelsen, D. P.
    Janjigian, Y. Y.
    Tang, L. H.
    Campbell, J.
    Fuqua, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] A phase II study of perioperative mFOLFOX plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ) and stomach.
    Sun, Weijing
    Saeed, Anwaar
    Mohd, Raed
    Al-Rajabi, Taiseer
    Kasi, Anup
    Veeramachaneni, Nirmal K.
    Al-Kasspooles, Mazin Francis
    Baranda, Joaquina Celebre
    Phadnis, Milind A.
    Godwin, Andrew K.
    Olyaee, Mojtaba
    Madan, Rashna
    Streeter, Natalie
    Nagji, Alykhan
    Williamson, Stephen K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345